Salarius Pharmaceuticals Inc. (NASDAQ:SLRX) previous close was $1.25 while the outstanding shares total 30.55M. The firm has a beta of 1.59. SLRX’s shares traded lower over the last trading session, losing -2.40% on 05/25/21. The shares fell to a low of $1.22 before closing at $1.22. Intraday shares traded counted 0.93 million, which was 13.48% higher than its 30-day average trading volume of 1.08M. The stock’s Relative Strength Index (RSI) is 45.38, with weekly volatility at 8.85% and ATR at 0.12. The SLRX stock’s 52-week price range has touched low of $0.63 and a $3.50 high.
Investors have identified the Biotechnology company Salarius Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $50.59 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Salarius Pharmaceuticals Inc. (SLRX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 41.65 million total, with 1.99 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.26 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SLRX sounds very interesting.
Is the stock of SLRX attractive?
In related news, Director, HANISH ARNOLD C bought 4,000 shares of the company’s stock in a transaction that recorded on Aug 21. The purchase was performed at an average price of 0.98, for a total value of 3,920. As the purchase deal closes, the Chief Executive Officer, Arthur David J. now bought 2,000 shares of the company’s stock, valued at 2,020. Also, Exec VP Finance, CFO, Rosenblum Mark J bought 5,000 shares of the company’s stock in a deal that was recorded on Aug 17. The shares were cost at an average price of 1.00 per share, with a total market value of 5,000. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.30%.